Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 113


Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.

Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann R, Hofmann WK, Fabarius A, Seifarth W; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; German CML Study Group.

PLoS One. 2015 Jun 18;10(6):e0129648. doi: 10.1371/journal.pone.0129648. eCollection 2015.


Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Ann Hematol. 2014 Jul;93(7):1167-76.


Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.

Bug G, Koschmieder S, Krauter J, Heuser M, Thol F, Wiebe S, Hofmann WK, Klein SA, Wegener G, Göhring G, Heit W, Hoelzer D, Ganser A, Ottmann OG.

Ann Hematol. 2014 Feb;93(2):193-202. doi: 10.1007/s00277-013-1873-3. Epub 2013 Aug 27.


Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.

Niederle N, Megdenberg D, Balleisen L, Heit W, Knauf W, Weiß J, Freier W, Hinke A, Ibach S, Eimermacher H.

Ann Hematol. 2013 May;92(5):653-60. doi: 10.1007/s00277-012-1660-6. Epub 2013 Jan 23.


Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.

Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely OA, Löffler J, Ruhnke M; IDEA study investigators.

Eur J Clin Microbiol Infect Dis. 2013 May;32(5):679-89. doi: 10.1007/s10096-012-1794-4. Epub 2012 Dec 28.


Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.

Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG).

Blood. 2011 Feb 10;117(6):1817-21. doi: 10.1182/blood-2010-04-282228. Epub 2010 Dec 7.


Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, Vicari AP, Lotz C, van Dorp S, Hol S, Greenberg PD, Heit W, Davis HL, Theobald M.

Cancer Immunol Immunother. 2011 Feb;60(2):161-71. doi: 10.1007/s00262-010-0929-7. Epub 2010 Oct 21.


Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A.

Blood. 2010 Jul 29;116(4):614-6. doi: 10.1182/blood-2010-03-272146. Epub 2010 Apr 26.


Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J.

J Clin Oncol. 2010 May 10;28(14):2356-64. doi: 10.1200/JCO.2009.27.6899. Epub 2010 Apr 5.


Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Döhner H, Heil G, Ganser A, Krauter J.

J Clin Oncol. 2010 Feb 1;28(4):578-85. doi: 10.1200/JCO.2009.23.0342. Epub 2009 Dec 28.


First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.

Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhöfer N, Rohrberg R, Söling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Döhner H, Emmerich B, Hallek M; German CLL Study Group (GCLLSG).

Blood. 2009 Oct 15;114(16):3382-91. doi: 10.1182/blood-2009-02-206185. Epub 2009 Jul 15.


Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

N Engl J Med. 2008 May 1;358(18):1909-18. doi: 10.1056/NEJMoa074306.


Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, Barth TE, Unterhalt M, Hiddemann W, Dreyling M, Klapper W; European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group.

Blood. 2008 Feb 15;111(4):2385-7. Epub 2007 Dec 12.


HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia.

Herr AL, Labopin M, Blaise D, Milpied N, Potter M, Michallet M, Heit W, Ferrara F, Esteve J, Arcese W, Ehninger G, Rowe JM, Kobbe G, Rosselet A, Bunjes D, Rio B, Brune M, Nagler A, Gorin NC, Frassoni F, Rocha V; Acute Leukemia Working Party or the European Group for Blood and Marrow Transplantation.

Leukemia. 2007 Jan;21(1):129-35. Epub 2006 Nov 23.


Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G.

J Clin Oncol. 2003 Dec 1;21(23):4413-22.


Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation.

Sezer O, Possinger K, Metzner B, Illiger HJ, Wattad M, Heit W, Fuss H, Schultze W.

J Clin Oncol. 2000 Sep 15;18(18):3319-20. No abstract available.


[Diagnostic and therapeutic splenectomy in hematological diseases].

Böhner H, Tirier C, Rötzscher VM, Heit W.

Dtsch Med Wochenschr. 1997 Feb 7;122(6):163-6. Review. German. No abstract available.


Indications for and results of splenectomy in different hematological disorders.

Böhner H, Tirier C, Rötzscher VM, Heit W.

Langenbecks Arch Chir. 1997;382(2):79-82.


[Splenectomy in osteomyelofibrosis. Indications and outcome].

Böhner H, Rötzscher VM, Tirier C, Heit W, Greiner J.

Chirurg. 1996 Oct;67(10):1016-9. German.


Simultaneous presence of t(11;14) and a variant Burkitt's translocation in the terminal phase of a mantle cell lymphoma.

Tirier C, Zhang Y, Plendl H, Weber-Matthiesen K, Langer W, Heit W, Schlegelberger B.

Leukemia. 1996 Feb;10(2):346-50.


Supplemental Content

Loading ...
Support Center